Cullinan Therapeutics, Inc. (CGEM)
| Market Cap | 999.43M +187.2% |
| Revenue (ttm) | n/a |
| Net Income | -208.34M |
| EPS | -3.47 |
| Shares Out | 64.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 567,509 |
| Open | 15.41 |
| Previous Close | 15.46 |
| Day's Range | 15.24 - 15.95 |
| 52-Week Range | 6.50 - 23.19 |
| Beta | -0.04 |
| Analysts | Strong Buy |
| Price Target | 33.45 (+115.39%) |
| Est. Earnings | Nov 5, 2026 |
About CGEM
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for CGEM stock is "Strong Buy." The 12-month stock price target is $33.45, which is an increase of 115.39% from the latest price.
News
Cullinan Therapeutics doses first patient in CLN-049 trial
Cullinan Therapeutics (CGEM) announced that the first patient has been dosed in its Phase 2 study of CLN-049, an investigational FLT3 T cell engager, in patients with relapsed/refractory acute myeloid...
Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia
CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, d...
Cullinan Therapeutics initiates NDA for Zipalertinib
The company stated: “Cullinan Therapeutics (CGEM) announced the initiation of a New Drug Application submission to the U.S. Food and Drug Administration for zipalertinib in combination with platinum-b...
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC
Cullinan Therapeutics price target raised to $35 from $30 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Cullinan Therapeutics (CGEM) to $35 from $30 and keeps a Buy rating on the shares. The company yesterday announced milestones across its…
Cullinan Therapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum
Multiple T cell engager programs are advancing, with a major December data update planned for CLN-978 across lupus, RA, and Sjögren's disease. Velinotamig is progressing in SLE and will expand into autoimmune cytopenias, while CLN-049 and zipalertinib are moving toward key regulatory milestones.
Cullinan Therapeutics share weakness provides buying opportunity, says TD Cowen
Cullinan Therapeutics (CGEM) enters Q4 with a catalyst-rich roadmap across its autoimmune and AML programs, as longer follow-up and multi-dose data for ‘978 in SLE, RA, and SjD could help…
Cullinan falls after pushing rheumatoid arthritis data to December
Shares of Cullinan Therapeutics (CGEM) after the company said CLN-978 data in systemic lupus erythematosus, difficult-to-treat rheumatoid arthritis, and Sjogren’s disease will be released in December....
Cullinan Therapeutics outlines Q4 2026 milestones across pipeline
Cullinan Therapeutics (CGEM) outlined fourth quarter 2026 milestones across its immunology and oncology pipeline. The Company plans to share the following immunology and oncology pipeline updates in Q...
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren's disease in December CLN-049 (FLT3 TCE) up...
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, ...
Cullinan Therapeutics price target raised to $40 from $39 at BTIG
BTIG raised the firm’s price target on Cullinan Therapeutics (CGEM) to $40 from $39 and keeps a Buy rating on the shares after the company presented Phase 3 REZILIENT3 data…
Cullinan Therapeutics Transcript: Study result
The phase III REZILIENT3 trial showed zipalertinib plus chemotherapy significantly improved progression-free survival and response rates in first-line EGFR exon 20 insertion mutation NSCLC, with strong efficacy in brain metastases and a manageable safety profile, supporting its potential as a new standard of care and substantial market adoption.
Cullinan Therapeutics Press release: Study result
Cullinan Therapeutics issued a press release on September 14, 2026, disclosing material business information to investors.
Cullinan Therapeutics Slides: Study result
Cullinan Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 14, 2026.
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modi...
Cullinan, Taiho announce Phase 3 REZILIENT3 trial met primary endpoint
Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (CGEM) announced results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy versus chemotherapy alone in the fi...
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase...
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposiu...
Cullinan, Taiho say results of Phase 3 trial selected for presentation
Taiho Oncology and Cullinan Therapeutics (CGEM) announced that results from the planned interim analysis of the Phase 3 REZILIENT3 trial have been selected for presentation in the Presidential Symposi...
Taiho, Cullinan Therapeutics study demonstrates statistically significant PFS
The company states: “Taiho Oncology Taiho Pharmaceutical Co, and Cullinan Therapeutics (CGEM) announced that the REZILIENT3 trial, a global Phase 3 clinical trial evaluating the combination of zipaler...
Cullinan Therapeutics price target raised to $47 from $46 at Clear Street
Clear Street analyst Kaveri Pohlman raised the firm’s price target on Cullinan Therapeutics (CGEM) to $47 from $46 and keeps a Buy rating on the shares after the Phase 3…
Cullinan Therapeutics reports Q2 EPS (81c), consensus (85c)
“At our recent Immunology Day event, we shared compelling initial clinical data for CLN-978 and velinotamig, two T cell engagers with potential to achieve immune reset and transform outcomes for…
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027
Cullinan Therapeutics Quarterly report: Q2 2026
Cullinan Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.